Clinical Trial Update: PDE5 Inhibitor for Alzheimer's Disease [Phase 2]

View source ↗

Summary

Imperial College London is conducting a Phase 2 trial of a PDE5 inhibitor for Alzheimer's disease; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: Imperial College London | Conditions: Alzheimer Disease | Phase 2 | Status: NOT_YET_RECRUITING